Cytochrome P450 (CYP) 2D6 is one of the most important enzymes involved in the metabolism of drugs. Multiple, clinically relevant, genetic variants of this... I Meijerman,LM Sanderson,PHM Smits,... - 《Drug Metabolism Reviews》 被引量: 64发表: 2007年 The clinical effectiveness and cost-eff...
CYP2D6is genotyped clinically for prediction of response to tamoxifen, psychotropic drugs and other medications. Phenotype prediction is dependent upon accurate genotyping. TheCYPAllele Nomenclature Committee maintains the allelic nomenclature forCYP2D6;however, in some cases, the list of polymorphisms associ...
CYP2D6 Inhibitors Drugs that inhibit CYP2D6 activity are likely to increase the plasma concentrations of certain medications, and, in some cases, adverse outcomes will occur (see Table 3 below right for a list of known inhibitors). Some drugs, such as fluoxetine, paroxetine, and quinidine, are...
The CYP2D6 enzyme is involved in the metabolism of many commonly prescribed drugs. The presence of polymorphisms in the CYP2D6 gene may modulate the enzyme level and activity affecting individual responses, to pharmacological treatment in drug level, response and adverse reactions. Aims. This study ...
Role of pharmacogenetics in variable response to drugs: focus on opioids. Expert Opin Drug Metab Toxicol. 2008;4(1):77–91. 15. Lotsch J, Skarke C, Liefhold J, Geisslinger G. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin ...
et al. Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4- selective inactivator (CYP3cide). Drug Metab. Dispos. 42, 1163– 1173 (2014). 16. Desta, Z., Ward, B.A., Soukhova, N.V. & Flockhart, D.A. Comprehensive ...
Of the clinically relevant pharmacogenes,CYP2D6is one of the most widely studied owing to its contribution to the Phase 1 metabolism of ~25% of clinically prescribed drugs, and high genetic variability within and between populations2. Drugs metabolised byCYP2D6include various antidepressants, antipsyc...
Many of these catalyze the oxidation of drugs and other xenobiotics in phase I metabolism [3]. As CYPs can bind their substrate and oxygen, but not the cofactor NADPH, they depend on electron transfer proteins such as NADPH cytochrome P450 oxidoreductase (CPR or POR) for reduction [4]. ...
Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review. Clin. Pharmacol. Ther. 2022, 112, 1318–1328. [Google Scholar] [CrossRef] Wang, X.; Wang, C.; Zhang, Y.; An, Z. Effect of pharmacogenomics ...
C ytochrome P450 2D6 (CYP2D6) is one of the most scrutinized phase I drug metabolizing enzymes due to its involvement in the metabolism and bioactivation of 20 to 25% of clinically used drugs. Among the long list of drugs and substrates are many antidepressants and antipsychotics, pain ...